Aims: Glutamatergic transmission may play a critical role in the pathogenesis of Parkinson's disease (PD). Electroacupuncture (EA) has been demonstrated to effectively alleviate PD symptoms. In this study, a potential glutamate-dependent mechanism underlying the therapeutic action of EA was investigated. Methods: The effects of EA stimulation on motor behaviors, dopamine contents, glutamate release, and group II metabotropic glutamate receptor (mGluR2/3) expression in unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats were examined. Results: Unilateral 6-OHDA lesions of the nigrostriatal system caused a marked increase in glutamate content in the ipsilateral cortex and striatum. mGluR2/3 protein expression and mGluR3 mRNA expression were reduced in the striatum. Noticeably, prolonged EA stimulation at 100 Hz significantly reversed these changes in the striatal glutamate system. Behaviorally, EA improved the motor deficits induced by 6-OHDA lesions. Intrastriatal infusion of an mGluR2/3 antagonist APICA blocked the improving effect of EA. Conclusions: These data collectively demonstrate that the group II mGluR-mediated glutamatergic transmission in the striatum is sensitive to dopamine depletion and may serve as a substrate of EA for mediating the therapeutic effect of EA in a rat model of PD.
Introduction
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by certain typical motor symptoms including tremors, bradykinesia, rigidity, and postural instability. The primary pathology is progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc), which results in the loss of dopaminergic innervation in the striatum and physiological disruptions of motor control [1, 2] . Current clinical pharmacotherapies for PD mainly focus on dopamine (DA) replacements. However, drug therapy makes patients prone to developing motor complications and psychiatric side effects in advanced disease stages [3] . Furthermore, the most recent therapeutic option, deep brain stimulation (DBS), is invasive and expensive surgical methods for treating strictly selected PD patients with severe motor fluctuations [4] . Acupuncture or electroacupuncture (EA) has long been used to alleviate the symptoms of patients with PD and improve their quality of life [5, 6] . In fact, studies have consistently demonstrated that high-frequency EA stimulation (100 Hz) alleviated movement disorders in various parkinsonian models, including the medial forebrain bundle (MFB)-transected rat model [7] [8] [9] [10] , the 6-hydroxydopamine (6-OHDA) lesion rat model [11] , the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesion mouse model [12] , and the rhesus monkey model [13] . Additionally, combined treatment with acupuncture reduced the effective dose and alleviated adverse effects of levodopa (L-dopa) [14] . It has been reported that acupuncture may improve the motor function of PD mice by increasing the DA efflux and turnover ratio of DA [15] . We have also observed that EA normalized the activity of several neurotransmitters including substance P and GABA in addition to DA in the basal ganglia to improve motor disabilities [10, 16] . Thus, EA is believed to impact multiple transmitter systems to restore the normal tone of neurotransmitters within basal ganglia and improve PD symptoms [17] .
Evidence suggests an increase in glutamatergic transmission in the basal ganglia motor circuitry, which plays a critical role in the clinical manifestation of PD [18] . Meshul et al. [19] reported that glutamate levels in the striatum were increased in 6-OHDAlesioned rats. A subthalamic nucleus (STN) lesion reversed the increase in striatal glutamatergic transmission and abnormalities in motor behavior of PD model [20] . It appears that inhibiting the elevated glutamatergic transmission in the striatum is of effectiveness in treating PD.
Metabotropic glutamate receptors (mGluRs) are emerging as a promising target for PD treatment [21] . Several preclinical studies have suggested that the activation of both group II and III mGluRs provided both symptom relief and neuroprotection in PD animals [22, 23] . In particular, group II mGluRs are important for the neuroprotective property based on the fact that activation of group II mGluRs inhibited presynaptic glutamate release in the basal ganglia [24] [25] [26] . Moreover, the mGluR2/3 agonist protected the nigrostriatal system, which translated into functional recovery of motor disabilities in a PD study [27] .
This study investigated whether changes in the glutamate system in the striatum occur in response to an experimental model of PD and whether EA can modify these changes to achieve its therapeutic effect. We used a rat PD model in which the nigrostriatal dopaminergic pathway was depleted by 6-OHDA. In the striatum of 6-OHDA-lesioned rats, glutamate contents, extracellular glutamate levels, and mGluR2/3 mRNA and protein expression were monitored by different biochemical assays. The effects of EA on 6-OHDA-induced changes in these parameters were assessed. Additionally, a set of neurobehavioral experiments were carried out to test the effects of an mGluR2/3 antagonist on the EA action in improving PD symptoms.
Materials and methods

Animals
The experiments were performed on adult male Sprague-Dawley rats weighing 180-200 g, which were supplied by the laboratory animal center at Capital Medical University. The rats were housed in a pathogen-free climate-controlled facility with food and water available ad libitum. The experimental procedures were approved by the Animal Care and Use Committee of Capital Medical University.
6-OHDA lesions of the nigrostriatal tract
Rats were anesthetized by an intraperitoneal injection of chloral hydrate (350 mg/kg) and positioned in a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA, USA). The rats received a single unilateral injection of 6-OHDA (8 lg; Sigma, St. Louis, MO, USA) dissolved in 4 lL of sterile water containing 0.2% of ascorbic acid into the right MFB at a flow rate of 1 lL/min. The stereotaxic coordinates of the injection were as follows: AP: À4.3 mm; ML: À1.5 mm; and DV: À7.5 mm, according to the stereotaxic atlas of Paxinos and Watson (1998). Animals with a sham lesion were similarly injected with vehicle alone (4 lL of sterile water with 0.2% of ascorbic acid). After injections, animals were kept warm and allowed to recover from anesthesia before being returned to the animal house for 1-week recovery from surgery.
EA stimulation
Rats were randomly divided into four groups: sham rats without EA, 6-OHDA-lesioned rats without EA, and 6-OHDA-lesioned rats treated with either 0-or 100-Hz EA. In EA groups, rats received a 6-OHDA lesion, followed by 0-or 100-Hz EA stimulation at two acupoints, Dazhui (GV14, just below the spinous process of the vertebra prominens) and Baihui (GV20, the midpoint of the line connecting the apexes of both ears on the parietal bone), as described previously [7, 10, 16] . Briefly, two stainless steel needles (0.25 mm in diameter, 5 mm in length) were inserted obliquely at the acupoints. Bidirectional square-wave electrical pulses (0.2 ms duration, 100 Hz), designated as EA, were given for 30 min (once daily for 6 days per week). The duration of EA stimulation was 2 or 4 weeks, that is, 12 or 24 times, respectively. The intensity of the stimulation was increased stepwise from 1 to 2 mA and then to 3 mA, with each step lasting for 10 min.
Behavioral assay
Behavioral tests were assessed the next day after 2 or 4 weeks of EA stimulation, that is, 3 or 5 weeks after 6-OHDA lesions, respectively. Changes in motor asymmetry were assessed by monitoring body rotations induced by subcutaneous injection of apomorphine. The lowest doses of apomorphine (0.05 and 0.1 mg/kg) triggered a sharp increase in the speed of the rotation within 30 min at 5 weeks after 6-OHDA lesion [28] , which was thought to correlate with more than 75% reduction of DA levels in the rat striatum [29, 30] . The effect of apomorphine (0.25 mg/kg) was also used to reflect the time-response curves for apomorphine in sensitivity during the period [31, 32] . In this experiment, a dose-response study (including 0.1, 0.25, 0.5, and 1.0 mg/kg of apomorphine) was performed to define an effective dose range after 2 weeks of 6-OHDA injection into MFB. It showed that 0.25 mg/kg of apomorphine (s.c.) induced sizable and consistent rotations (data not shown). As a result, we used the dose of 0.25 mg/kg to validate the 6-OHDA lesion at 3 as well as 5 weeks postlesion in this study. The net number of turns was determined by contralateral turns minus ipsilateral turns in 30 min [7, 15, 16] . The motor coordination of rats was evaluated using rotarod treadmills (Stoelting Company, Wood Dale, IL, USA). The time that rats stayed on the treadmills was calculated. The locomotor activity was recorded as total movement distance, total movement time, and mean velocity across a 30-min recording period. All behavioral experiments were examined in a blinded fashion.
In vivo microdialysis
Rats were anesthetized for implantation of guide cannulas. A hole was drilled at 1.0 mm rostral to bregma and 2.5 mm lateral to midline. A stainless steel guide cannula (15 mm long, 21-gauge; CMA, Solna, Sweden) was placed with the tip located 3.5 mm below the dura and attached to the skull using a thin layer of dental cement. A microdialysis probe (2 mm in length and 0.5 mm in diameter; CMA, Sweden) with a 20 kDa cutoff was inserted into the guide cannula and perfused with artificial cerebrospinal fluid (140 mM NaCl, 3.4 mM KCl, 1.5 mM CaCl 2 , 1.0 mM MgCl 2 , 1.4 mM NaH 2 PO 4 , 4.85 mM Na 2 HPO 4 , and 5.4 mM glucose, pH 7.4) at 2 lL/min until the baseline was stabilized. Samples were collected every 20 min for the detection of neurotransmitters [16] .
High-performance liquid chromatography (HPLC)
All the samples from tissue or microdialysis were injected into a HPLC system (Model 5600A; CoulArray Detector System, ESA, Chelmsford, MA, USA) for analysis. Concentrations of DA were quantified by a modified method of HPLC combined with electrochemical detection (HPLC-ECD) [10] . For glutamate assays, the tissue samples or dialysates were mixed with the same volume of o-phthalaldehyde (Sigma, USA) for precolumn derivatization. The mobile phase for isocratic elution consisted of 100 mM NaH 2 PO 4 (pH 3.5), 10% methanol, and 0.5 mM Na 2 EDTA.
Intrastriatal injections of group II mGluR agents
To explore whether group II mGluRs mediate the effect of EA, the mGluR2/3 antagonist (RS)-1-amino-5-phosphonoindan-1-carboxylic acid (APICA) and the agonist 2R, 4R-4-aminopyrrolidine-2,4-dicarboxylate (APDC) were used. One week after 6-OHDA injections, a metal guiding cannula (22-gauge) with threaded plastic casing was permanently attached to the skull with miniature screws and dental cement. The intracerebral end of the guide cannula was placed 1.0 mm posterior, 1.6 mm lateral, and 4.0 mm below the bregma. For intrastriatal injections, the dummy cannula was replaced temporarily by a small-bore (28-gauge) metal cannula protruding 0.5 mm from the internal end of the guide cannula. This cannula was connected by flexible tubing to a Hamilton syringe. A group II mGluR agent or saline was infused in a volume of 1 lL. EA stimulation was applied 20 min after drug injection.
Immunohistochemistry and Western blot
Immunohistochemistry and immunoblot of tyrosine hydroxylase (TH) were performed as described previously [9, 16] . Immunoblot of mGluR2/3 proteins was performed following an early protocol [33] . A rabbit mGluR2/3 (Millipore) antibody was used for immunostaining. Antibody conjugated with IRDye TM 700 red (Rockland) and LI-COR Odyssey infrared double-fluorescence imaging system (American Company LI-COR) were used to visualize primary antibody signals.
Real-time polymerase chain reaction (RT-PCR)
To measure mRNA levels of mGluR2 and mGluR3, a real-time quantitative PCR analysis was performed using a method previously described by Zhang et al. [34] . SYBR Green (Stratagene)-based quantitative PCR was performed using primers designed to target the mGluR2 receptor (forward: 5 0 -TGCGTG 
Statistical analysis
The data were reported as means AE SEM. One-or two-way analysis of variance (ANOVA) was used, as appropriate, followed by the Newman-Keuls post hoc test for comparison of groups. P < 0.05 is the criterion for statistical significance.
Results
EA improved motor symptoms in 6-OHDAlesioned rats A hemiparkinsonian rat model was developed by injecting 6-OHDA into the right MFB which caused a unilateral lesion of the nigrostriatal system. The apomorphine-induced rotation was first analyzed, and the results are shown in Figure 1A . The results from two-way ANOVA showed significant effects [groups: F (3, 36) = 23.48, P < 0.001; weeks: F (2, 72) = 53.25, P < 0.001; and interactions of groups and weeks: F (6, 72) = 8.24, P < 0.001]. Sham rats had a minimal change in rotation responses, while the 6-OHDA-lesioned rats exhibited 206 AE 42.31 and 301 AE 51.03 turns/30 min at 3 and 5 weeks after 6-OHDA lesions, respectively. The 100-Hz EA effectively decreased the rotation numbers after 2 and 4 weeks of EA treatment respectively tested at 3 and 5 weeks after the lesion. Similar to a prior report [9] , no obvious improvement in the motor symptom was observed after EA stimulation at 0 Hz. We next performed the rotarod test after 4 weeks of EA treatment. The performance latency on the accelerating rotarod was markedly decreased in 6-OHDA-lesioned rats compared with sham rats, while the 100-but not 0-Hz EA significantly reversed this decrease ( Figure 1B) . Similar results were consistently observed in the other motor activities surveyed. Two-way ANOVA showed significant effects [groups: F (3, 36) = 17.85, P < 0.001; weeks: F (2, 72) = 33.73, P < 0.01; and interactions of groups and weeks: F (6, 72) = 4.19, P = 0.01] ( Figure 1C) . A one-way ANOVA followed by the Newman-Keuls post hoc test showed 6-OHDA lesions reduced the total movement distance ( Figure 1C ). Similar data showed that 6-OHDA lesions also reduced the total movement time ( Figure 1D ) and the mean velocity ( Figure 1E) , while EA at 100 Hz partially restored these motor activities at 5 weeks after 6-OHDA lesions. These data collectively support that the 100-Hz EA possesses the ability to alleviate the abnormal movement symptoms triggered by 6-OHDA lesions.
EA did not alter the DA neuronal loss in 6-OHDAlesioned rats a minimal impact on this loss (Figure 2A) . Like the SNc, striatal loss of TH-positive fibers was not altered by EA stimulation ( Figure 2B ). In Western blot analysis, we found no difference in TH protein levels in the ventral midbrain between 6-OHDAlesioned rats without EA and lesioned rats with EA at either 0 or 100 Hz ( Figure 2C) . Furthermore, HPLC analysis showed that 6-OHDA lesions caused a substantial reduction of DA contents in the lesioned striatum. The 100-Hz EA did not recover the loss of striatal DA contents after 4 weeks of treatment (Figure 2D) . These data indicate that EA has a limited effect on dopaminergic deficits in the nigrostriatal pathway in 6-OHDAlesioned rats.
EA modulated glutamatergic components in 6-OHDA-lesioned rats An increased drive in the corticostriatal glutamatergic projection likely plays a key role in the pathophysiology of PD [35, 36] . As shown in Figure 3A , 6-OHDA lesions elicited a significant increase in glutamate contents in the ipsilateral cortex (52.8 AE 0.7 lg/g) compared to the contralateral cortex (43.2 AE 2.0 lg/g, F = 35.39, P < 0.05) or the sham lesioned side (44.8 AE 1.2 lg/g, F = 35.49, P < 0.05). After 4 weeks of EA treatment, the increase in cortical glutamate contents was reduced. Similar results were observed in the striatum ( Figure 3B ). The level of glutamate contents in the contralateral side remained unchanged in the cortex and striatum in all groups of rats. Thus, EA effectively reversed the 6-OHDAinduced increase in glutamate contents in the cortex and striatum, while it had no effect on basal levels of glutamate in the two regions.
We next carried out in vivo microdialysis combined with HPLC assays of dialysate samples to monitor extracellular glutamate levels in the striatum. There was a significant increase in glutamate levels in the lesioned side of the striatum compared to the contralateral striatum ( Figure 3C ). The reduction tendency of glutamate release was observed in the striatum after 2 weeks of 100-Hz EA ( Figure 3C ; although F = 3.95, P > 0.05), and the elevated glutamate release was significantly reduced after 4 weeks of 100-Hz EA ( Figure 3D ; F = 9.04, P < 0.01). Moreover, changes in glutamate levels in the striatum correlated with changes in locomotion activity after 2 ( Figure 3E ) and 4 ( Figure 3F ) weeks of EA treatment. These results suggest that prolonged EA stimulation reduced the increase in striatal glutamate release in response to 6-OHDA, which occurs in a close correlation with the magnitude of motor improvement.
EA modulated mGluR2/3 expression
Presynaptic group II mGluRs (mGluR2/3) have been reported to function as autoreceptors to inhibit glutamate release [37] . The present study thus examined whether group II mGluRs contribute to the beneficial effect of EA stimulation. We first tested whether 6-OHDA lesions cause any change in group II mGluR expression and whether EA affects group II mGluR expression in striatal neurons. At the mRNA level, we detected mGluR2 and mGluR3 mRNA signals using quantitative RT-PCR. We found that that mGluR3 mRNA levels were significantly reduced in the striatum of 6-OHDA-lesioned rats, consistent with the results from an early in situ hybridization study [38] . The 100-Hz EA effectively increased mGluR3 mRNA expression ( Figure 4B ). However, mGluR2 mRNA expression was less affected by 6-OHDA lesions ( Figure 4A ). EA stimulation decreased mGluR2 mRNA expression in the lesioned striatum of 6-OHDA rats. At the protein level, mGluR2/3 protein expression is shown in Figure 4C . Using an antibody that detects both mGluR2 and mGluR3, we found that 6-OHDA-lesioned rats had a decreased level of mGluR2/3 proteins in the striatum. This decrease was reversed by EA stimulation. The data from mRNA and protein measurements seem to indicate that 6-OHDA lesions cause a decrease in group II mGluR, particularly mGluR3, expression in the striatum, and EA is able to correct this decrease.
The mGluR2/3 antagonist blocked the motor effect of EA
To investigate the functional role of mGluR2/3, we tested the effect of an mGluR2/3 antagonist, APICA, on EA-induced motor improvements. Similar to the above finding, 6-OHDA significantly reduced the total movement distance ( Figure 5A ). The 100-Hz EA stimulation partially blocked this motor deficit. Interestingly, chronic intrastriatal infusion of APICA (10 lg, once daily for 2 weeks, 20 min prior to EA) reduced the EA effect in improving motor activity. Similarly, APICA partially blocked the EA effect on other motor activities, including the total movement time and the mean movement velocity (Figure 5B, C) . These behavioral data indicate that mGluR2/3 activity contributes to the ability of EA to improve motor deficits in 6-OHDA-lesioned rats.
EA affected mGluR2/3-regulated glutamate release
As previously mentioned, presynaptic mGluR2/3 inhibit glutamate release [37] . Consistent with this, blocking mGluR2/3 through APICA perfused into the striatum by reverse microdialysis elevated the level of extracellular glutamate. A short-term EA stimulation (100 Hz for 60 min) attenuated this elevation ( Figure 6 ). After the EA stimulation was terminated, reperfusion of APICA into the striatum again elicited a moderate increase in extracellular glutamate levels. This increase was reversed by coperfusion of the group II mGluR2/3 agonist APDC. These results provide further evidence for a notion that EA enhances the mGluR2/3 tone to modulate glutamate levels in the striatum.
Discussion
This study investigated a group II mGluR-mediated glutamatergic system in its responses to dopamine lesions and its roles in processing EA effects. The data obtained in this study seem to support that EA exerted its effects on motor behaviors at least in part through a group II mGluR-dependent mechanism. For example, EA increased the expression of mGluR3 in the striatum. Importantly, inhibition of group II mGluRs reversed the effects of EA. Meanwhile, EA attenuated the increase of extracellular glutamate levels elicited by a group II mGluR antagonist.
EA improves motor symptoms via a mechanism involving glutamate
Our previous and present studies showed that the 100-Hz EA significantly alleviated abnormal motor behaviors but had no obvious effect on the loss of dopaminergic neurons in the SNc and dopaminergic fibers in the striatum [10, 15] . Multiply therapeutic approaches have been found to be effective in improving motor Figure 3 Effects of EA stimulation on the glutamate contents and extracellular glutamate levels in the striatum and cortex. HPLC analysis was performed of glutamate contents in the cortex (A) and the striatum (B) after 4 weeks of EA stimulation in 6-OHDA lesions. In vivo microdialysis combined with HPLC-ECD was used to monitor the extracellular glutamate levels in the striatum after 2 weeks (C) and 4 weeks (D) of EA stimulation, respectively. One-way ANOVA: (A) F = 35.39, P < 0.05; (B) F = 39.52, P < 0.001; (C) F = 3.91, P < 0.05; (D) F = 9.04, P < 0.001. *P < 0.05, **P < 0.01, ***P < 0.001 vs. sham group; # P < 0.05 vs. model group; n = 6. There existed a correlated relationship between extracellular glutamate levels in the striatum and locomotor behavior of 6-OHDA rats after 2 weeks (E) and 4 weeks of EA stimulation (F), respectively; n = 6. function under the condition that these approaches did not increase DA levels in the striatum or regenerate dopaminergic neurons in the SNc. For example, intracerebral injection of glial cell line-derived neurotrophic factor alleviated parkinsonian behavior but not DA levels in the striatum [39, 40] . Similarly, DBS did not increase DA levels in the striatum of patients with PD [41] [42] [43] . This study has also found that the 100-Hz EA did not recover the loss of striatal DA contents in this severe 6-OHDAdamaged model. Although the enhancement of dopamine availability [15] or modulation of presynaptic dopamine transporter and postsynaptic dopamine receptors [44] was found, the symptomatic improvement effects of EA may not be limited to the dopaminergic system but involve other modulatory pathways or neurotransmitters as well. We have also identified that behavioral alleviation with EA stimulation may be related to modulation of glutamate and acetylcholine release in the striatum [16] . Thus, the effects of EA in this study did not result from its direct action on the dopamine loss, but from its influence over other systems such as glutamatergic transmission. Evidence has shown that the loss of nigrostriatal dopaminergic neurons led to increased glutamatergic transmission in the striatum [45, 46] . In detail, the DA depletion was associated with an increased corticostriatal glutamate activity [19, 46, 47] and with a higher level of extracellular glutamate in the striatum [46, 48] . Consistent with these early observations, we found in the present study that dopamine lesions induced an increase in glutamate levels in the cortex and striatum. This seems to support a notion that striatal glutamatergic transmission is enhanced in response to dopamine lesions. However, the change in striatal glutamate levels was time-dependent. For example, while Abarca and Bustos [44] did not find any change in glutamate outflow 7 days after 6-OHDA infusion, Jonkers et al. observed an increase in glutamate overflow 18-20 days after 6-OHDA injection [45] or 1 month later [41] . Thus, it appears that the close association between striatal glutamate responses and behavioral impairments occurs at a defined time window following 6-OHDA lesions. Clarification of such time-dependent associations is of great importance in terms of treatment of PD. In general, a chronic intervention, such as a prolonged but not acute EA treatment, seems to be effective in producing a delayed and sustained inhibitory effect on striatal glutamate levels and motor behavior in the PD model.
Several glutamatergic pathways are involved in the pathophysiology of PD, including the glutamatergic projection from the cortex to the striatum [49, 50] . As such, the reversal of abnormal striatal glutamatergic transmissions is thought to have a therapeutic value [20] . Indeed, amantadine, a weak antagonist of NMDA glutamate receptors, has been approved for treating PD [51] . EA is also believed to affect the glutamate system to achieve its therapeutic effects based on a previous study conducted in this laboratory. A glutamate level in the striatum correlated well with the damage to DA neurons in the SNc and behavioral impairments, and EA was able to significantly decrease the elevated striatal glutamate level in MFB-transected rats [16] . The current study also revealed that EA reduced the content and extracellular glutamate release in the striatum. Moreover, extracellular glutamate levels showed a significant correlation with locomotor activities after 2 weeks and 4 weeks of EA treatment. Although the specific glutamatergic pathway affected by EA needs to be proven experimentally, the inhibition of the corticostriatal glutamatergic transmission is thought at least in part to mediate the effects of chronic EA. Future studies will investigate the effect of chronic EA treatment on the basal striatal glutamate output.
The role of group II mGluRs in EA alleviation of PD Available data suggest that group II mGluRs play a role in the PD development and are thus a central site for pharmacotherapies. Selective agonists of group II mGluRs reduced the hyperactivity of corticostriatal fibers in response to dopaminergic denervation [38, 52] . Activation of group II mGluRs also relieved muscle rigidity [53] and akinesia [54] in rodent models of PD. Intracerebroventricular or intranigral injection of mGluR2/3 agonists reduced akinesia in reserpine-treated rats [38, 54] .
Strikingly, EA at 100 Hz significantly increased mGluR3 mRNA expression in the 6-OHDA-lesioned side of the striatum. Similarly, protein expression of mGluR2/3 was also increased with longterm EA treatment. Thus, EA seems to enhance the mGluR2/3 tone in the local site. It is assumed that increased mGluR2/3 activity may autoinhibit presynaptic glutamate release, leading to a lower extracellular glutamate level and improvement of motor deficits. To confirm this, the effect of the mGluR2/3 antagonist APICA on EA action was examined. We found APICA injected into the striatum blocked the behavioral effects of EA. Thus, group II mGluRs were involved in mediating EA effects. Furthermore, perfusion of APICA into the striatum elicited an increase in extracellular glutamate levels, which was attenuated by EA. This provides direct evidence that the group II mGluRs inhibit glutamate release and EA was able to affect group II mGluRs in this capacity.
Conclusion
This study has shown that the group II mGluR-mediated glutamatergic transmission in the striatum is sensitive to dopamine depletion and its roles in processing EA effects. EA effectively alleviated motor disabilities in unilateral 6-OHDA-lesioned rats. The effects of EA on motor behaviors were at least in part through group II mGluRs-mediated modulation of glutamatergic transmission. Conversely, the beneficial effects of EA treatment were abolished by group II mGluR antagonist. These evidences suggested Figure 6 Effects of EA on the mGluR2/3 antagonist-induced increase in glutamate levels in the striatum. Note that reverse dialysis of the mGluR2/ 3 antagonist APICA (100 lM) produced an increase in extracellular glutamate levels in the striatum of normal rats. This increase became significantly less in the presence of EA stimulation (100 Hz, 60 min) or the group II mGluR agonist APDC (50 lM). Data are expressed as mean AE SEM (n = 5). *P < 0.05 vs. baseline; # P < 0.05 vs. APICA.
that the modulatory roles of EA might depend on group II mGluR activation and would be a useful therapeutic avenue for PD.
